DD209455A5 - Verfahren zur herstellung von ascorbinsaeureethern - Google Patents

Verfahren zur herstellung von ascorbinsaeureethern Download PDF

Info

Publication number
DD209455A5
DD209455A5 DD83247195A DD24719583A DD209455A5 DD 209455 A5 DD209455 A5 DD 209455A5 DD 83247195 A DD83247195 A DD 83247195A DD 24719583 A DD24719583 A DD 24719583A DD 209455 A5 DD209455 A5 DD 209455A5
Authority
DD
German Democratic Republic
Prior art keywords
ascorbic acid
alkyl
compound
formula
acid
Prior art date
Application number
DD83247195A
Other languages
German (de)
English (en)
Inventor
Gary A Koppel
Russell L Barton
Jesse R Bewley
Stephen L Briggs
Joseph W Parton
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of DD209455A5 publication Critical patent/DD209455A5/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/26—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D307/30—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D307/32—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D307/56—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D307/62—Three oxygen atoms, e.g. ascorbic acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Furan Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
DD83247195A 1982-01-15 1983-01-12 Verfahren zur herstellung von ascorbinsaeureethern DD209455A5 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US33934482A 1982-01-15 1982-01-15

Publications (1)

Publication Number Publication Date
DD209455A5 true DD209455A5 (de) 1984-05-09

Family

ID=23328588

Family Applications (1)

Application Number Title Priority Date Filing Date
DD83247195A DD209455A5 (de) 1982-01-15 1983-01-12 Verfahren zur herstellung von ascorbinsaeureethern

Country Status (16)

Country Link
EP (1) EP0086554A1 (fr)
JP (1) JPS58131978A (fr)
KR (1) KR840003247A (fr)
AU (1) AU1035183A (fr)
CA (1) CA1181078A (fr)
DD (1) DD209455A5 (fr)
DK (1) DK14283A (fr)
ES (2) ES8403118A1 (fr)
FI (1) FI830078A7 (fr)
GB (1) GB2114571A (fr)
GR (1) GR77897B (fr)
IL (1) IL67646A0 (fr)
PL (1) PL240125A1 (fr)
PT (1) PT76083B (fr)
RO (1) RO86439B (fr)
ZA (1) ZA83173B (fr)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4552895A (en) * 1983-03-14 1985-11-12 Eli Lilly And Company Furo[3,2-b]furan-2-(3H)-ones
JPS6058973A (ja) * 1983-09-13 1985-04-05 Mitsubishi Yuka Yakuhin Kk γ−プチロラクトン誘導体及びそれを有効成分とする免疫調節剤
WO1986007592A1 (fr) * 1985-06-18 1986-12-31 Takeda Chemical Industries, Ltd. Derives d'acide ascorbique, leur procede de preparation, et preparations les contenant
JPS60130582A (ja) * 1983-12-19 1985-07-12 Takeda Chem Ind Ltd 食品用酸化防止剤,アスコルビン酸誘導体およびその製造法
WO1986006720A1 (fr) * 1985-05-17 1986-11-20 Takeda Chemical Industries, Ltd. Derives d'acide ascorbique, production desdits derives et preparation pharmaceutique pouvant en resulter
JPS60139619A (ja) * 1983-12-27 1985-07-24 Mutsuyuki Kochi O−ベンジリデン−アスコルビン酸又はその塩よりなる抗腫瘍剤
JP2515556B2 (ja) * 1986-08-29 1996-07-10 武田薬品工業株式会社 ヒドロキシブテノライド誘導体およびその製造法
JP2752080B2 (ja) * 1988-03-09 1998-05-18 株式会社日本ハイポックス アスコルビン酸誘導体及びその製造方法並びにアスコルビン酸誘導体からなる抗酸化剤
JPH0730066B2 (ja) * 1988-03-09 1995-04-05 株式会社日本ハイポックス アスコルビン酸誘導体及びアスコルビン酸誘導体からなる抗酸化剤
EP0359036B1 (fr) 1988-09-01 1997-03-26 Takeda Chemical Industries, Ltd. Dérivés de fumagillol
JP3058282B2 (ja) * 1989-09-11 2000-07-04 株式会社日本ハイポックス アスコルビン酸誘導体
US5095126A (en) * 1990-01-12 1992-03-10 Ohio State University Research Foundation Efficient synthesis for optically pure stereogenically labile 4-substituted-2-hydroxytetronic acids
US5210220A (en) * 1990-03-07 1993-05-11 Hoffmann-La Roche Inc. Method for preparing derivatives of ascorbic acid
US5270336A (en) * 1990-03-16 1993-12-14 Merrell Dow Pharmaceuticals Inc. Ascorbic acid derivatives
EP0446539A1 (fr) * 1990-03-16 1991-09-18 Merrell Dow Pharmaceuticals Inc. Dérivé de l'acide ascorbique
JPH0429989A (ja) * 1990-05-24 1992-01-31 Nisshin Flour Milling Co Ltd L―アスコルビン酸誘導体の製造法
GB9026114D0 (en) * 1990-11-30 1991-01-16 Norsk Hydro As New compounds
GB9201274D0 (en) * 1992-01-21 1992-03-11 Norsk Hydro As New compounds
GB9201275D0 (en) * 1992-01-21 1992-03-11 Norsk Hydro As New compounds
TW325997B (en) * 1993-02-02 1998-02-01 Senju Pharma Co Pharmaceutical composition for preventing and treating retinal diseases
RU2126398C1 (ru) * 1993-02-05 1999-02-20 Плива, Фармацеутска, Кемийска, Прехрамбена и Козметичка Индустрия Дионичко Друштво Загреб Производные аминоаскорбиновой кислоты, способы их получения и производные галоидаскорбиновой кислоты
US6114355A (en) * 1993-03-01 2000-09-05 D'amato; Robert Methods and compositions for inhibition of angiogenesis
US5629327A (en) * 1993-03-01 1997-05-13 Childrens Hospital Medical Center Corp. Methods and compositions for inhibition of angiogenesis
US6228879B1 (en) 1997-10-16 2001-05-08 The Children's Medical Center Methods and compositions for inhibition of angiogenesis
US5504074A (en) 1993-08-06 1996-04-02 Children's Medical Center Corporation Estrogenic compounds as anti-angiogenic agents
US6908910B2 (en) 1993-08-06 2005-06-21 The Children's Medical Center Corporation Estrogenic compounds as anti-mitotic agents
EP1920773B1 (fr) 1996-11-05 2011-01-05 The Children's Medical Center Corporation Thalidomide et dexamethasone pour le traitement des tumeurs
EP0875246A1 (fr) * 1997-04-04 1998-11-04 Showa Denko Kabushiki Kaisha Préparation pharmaceutique de dérivés d'acide ascorbique pour le traitement du cancer
JP3440263B2 (ja) * 1998-03-27 2003-08-25 エルジー・ライフ・サイエンシーズ・リミテッド 新規アスコルビン酸誘導体及びその調製方法
US6673828B1 (en) 1998-05-11 2004-01-06 Children's Medical Center Corporation Analogs of 2-Phthalimidinoglutaric acid
US7087592B1 (en) 1999-08-23 2006-08-08 Entre Med, Inc. Compositions comprising purified 2-methoxyestradiol and methods of producing same
WO2001056566A1 (fr) * 2000-02-01 2001-08-09 Mutsuyuki Kochi Compositions inhibitrices de neovascularisation et procede correspondant
ES2243466T3 (es) * 2000-03-31 2005-12-01 Angiogene Pharmaceuticals Ltd Terapias en dosis divididas con actividad dañina vascular.
EP1409494B1 (fr) * 2001-07-26 2006-04-05 Tagra Biotechnologies Ltd Derives stabilises d'acide ascorbique-3-phosphate
KR100971599B1 (ko) 2002-05-15 2010-07-20 비에이취엔 가부시끼가이샤 혈관 관련 질환의 예방 또는 치료를 위한 조성물
EP1939192A1 (fr) * 2006-12-28 2008-07-02 Neuropharma S.A. Dérivés de cyclopentanone, procédé pour la synthése et utilisation de ceux-ci
FR2955493B1 (fr) * 2010-01-28 2012-02-24 Oreal Utilisation de derives d'acide ascorbique en coloration des fibres keratiniques humaines, composition les comprenant, procede de coloration et dispositif
JP5602456B2 (ja) * 2010-02-24 2014-10-08 日本精化株式会社 アスコルビン酸誘導体
WO2015048121A1 (fr) * 2013-09-25 2015-04-02 University Of Florida Research Foundation, Inc. Promédicaments de la vitamine c et leurs utilisations
US10105407B2 (en) * 2015-06-09 2018-10-23 John P. Crow, JR. Methods of extraction of nitrosylated or nitrated derivatives of ascorbic acid from myriciaria dubia and methods of synthesis thereof
WO2017093354A1 (fr) 2015-11-30 2017-06-08 INSERM (Institut National de la Santé et de la Recherche Médicale) Antagonistes de nmdar pour le traitement de maladies associées à l'angiogenèse

Also Published As

Publication number Publication date
FI830078L (fi) 1983-07-16
ES518968A0 (es) 1984-03-01
ES8502698A1 (es) 1985-01-16
ES525239A0 (es) 1985-01-16
RO86439B (ro) 1985-03-31
DK14283A (da) 1983-07-16
CA1181078A (fr) 1985-01-15
AU1035183A (en) 1983-07-21
DK14283D0 (da) 1983-01-14
EP0086554A1 (fr) 1983-08-24
ZA83173B (en) 1984-08-29
GB8300907D0 (en) 1983-02-16
ES8403118A1 (es) 1984-03-01
PT76083B (en) 1986-01-09
FI830078A0 (fi) 1983-01-10
FI830078A7 (fi) 1983-07-16
PT76083A (en) 1983-02-01
JPS58131978A (ja) 1983-08-06
IL67646A0 (en) 1983-05-15
KR840003247A (ko) 1984-08-20
GR77897B (fr) 1984-09-25
PL240125A1 (en) 1984-04-24
GB2114571A (en) 1983-08-24
RO86439A (fr) 1985-03-15

Similar Documents

Publication Publication Date Title
DE2915037C3 (de) Neue N-substituierte Moranolinderivate
EP0086554A1 (fr) Ethers de l'acide ascorbique et composés apparents
US4552888A (en) Ascorbic acid ethers in angiogene
EP0247320A2 (fr) 5-Arylalkyl-4-alkoxy-2(5H)-furanones, produits intermédiaires et leur procédé de préparation, ainsi que leur application comme agents à activité thérapeutique
DE2923368A1 (de) Neue 5-fluor-( beta -uridin oder 2'-desoxy- beta -uridin)-derivate, verfahren zur herstellung derselben und carcinostatische mittel mit einem gehalt derselben
DE2839388A1 (de) Imidazolylvinylaether und deren verwendung
DE60131416T2 (de) Chirale fluochinolon-argininsalzformen
DE3033895A1 (de) Psoralene, verfahren zu deren herstellung und diese enthaltende pharmazeutische praeparate
DE69102477T2 (de) 3-Aminochroman-Derivate, Verfahren zu deren Herstellung und diese enthaltende pharmazeutische Zusammensetzungen.
CH643830A5 (de) Bis-moranolin-derivate.
DE69500329T2 (de) Neue Triazol-Verbindung mit fungizider Wirkung, deren Herstellung und Verwendung
DE3438244C2 (fr)
DE3021169A1 (de) Pivaloyloxymethyl-2-propylpentanoat, verfahren zu seiner herstellung und diese verbindung enthaltende arzneimittel
DE68905361T2 (de) Trienische Derivate mit chromenischer Struktur, Verfahren zu deren Herstellung und diese enthaltende pharmazeutische Zusammenstellungen.
DE3709699C2 (de) 5-Fluoruracil-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung
DE2723450A1 (de) Uracilderivate und verfahren zu ihrer herstellung
DE2909646B1 (de) N-Alkenylmoranolinderivate
DE2650231A1 (de) Neue imidazolverbindungen, verfahren zu ihrer herstellung und diese enthaltende arzneimittel
DE69809564T2 (de) 2- 4-[4-(4,5-dichlor-2-methylimidazol-1-yl)butyl]piperazin-1-yl -5-fluorpyrimidin, seine herstellung und therapeutische verwendung
DE2932357A1 (de) Crotonamidderivate und sie enthaltende carcinostatische arzneimittel
DE1545581A1 (de) Neue Penicillinaldehyde und Verfahren zu deren Herstellung
DE1645901C3 (de) gamma-(4-Alkylp!peridino)-p-fluorbutyrophenone und Verfahren zu ihrer Herstellung
DE3146867A1 (de) Aether von substituierten hydroxymethylpyrazinen
DE2351184A1 (de) Isochinolinderivate, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneipraeparate
CH687001A5 (de) Pharmazeutisches Praeparat zur Modulierung der Immunreaktion.